The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies
Thrombosis Research · 2024
DOI: 10.1016/j.thromres.2023.11.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis Research, 2024. Verfasst von Ivan D Tarandovskiy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, United States of America. Hauptthemen laut MEDLINE: Thrombin, Thrombosis. Die Arbeit nennt 62 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Growing evidence supports the importance of factor (F) XI activation for thrombosis and hemostasis as well as inflammation and complement systems. In this study, we evaluated the effect of activated FXI (FXIa) on the detection of factor deficiencies by global hemostasis assays of thrombin generation (TG), plasmin generation (PG), and clot formation and lysis (CFL). MATERIALS AND METHODS: An absorbance and fluorescence microplate assay was used to simultaneously observe TG, PG, and CFL in FV-, FVII-, FVIII-, and FIX-deficient plasmas supplemented with purified factors. Coagulation was initiated with tissue factor with or without FXIa in the presence of tissue plasminogen activator. Thrombin and plasmin peak heights (TPH and PPH), maximal clot density (MCD), times to clotting (CT), thrombin and plasmin peaks (TPT and PPT) and clot lysis (LyT) and a new parameter, clot lifetime (LiT), were evaluated. RESULTS: TG/CFL were elevated by the FXIa at low FV (below 0.1 IU/mL), and at FVIII and FIX above 0.01 IU/mL. FXIa affected PG only at low FV and FVII. At high factor concentrations, FXIa reduced MCD. Thrombin and plasmin substrates had effect on CT, LyT, LiT and MCD parameters. CONCLUSIONS: FXIa reveals new relationships between TG, PG and CFL parameters in factor deficiencies suggesting potential benefits for discrimination of bleeding phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, United States of America.
- Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, United States of America. Electronic address: mikhail.ovanesov@fda.hhs.gov.
Zitieren
APA
Tarandovskiy, I. D., & Ovanesov, M. V. (2024). The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies. Thrombosis Research. https://doi.org/10.1016/j.thromres.2023.11.024
Vancouver
Tarandovskiy ID, Ovanesov MV. The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies. Thrombosis Research. 2024. doi:10.1016/j.thromres.2023.11.024
BibTeX
@article{Tarandovskiy2024,
author = {Tarandovskiy, Ivan D and Ovanesov, Mikhail V},
title = {The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies},
journal = {Thrombosis Research},
year = {2024},
doi = {10.1016/j.thromres.2023.11.024}
}
EUVIMED